NAV

Roxatidine acetate

Identification

Generic Name
Roxatidine acetate
DrugBank Accession Number
DB08806
Background

Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 348.4366
Monoisotopic: 348.204907394
Chemical Formula
C19H28N2O4
Synonyms
  • Pifatidine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

For the treatment of disorders of the upper gastro-intestinal region that are due to an excess of hydrochloric acid in the gastric juice, i.e. duodenal ulcers, benign gastric ulcers. Also for prophylaxis of recurrent gastric and duodenal ulcers

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Roxatidine acetate suppresses the effect of histamine on the parietal cells of the stomach (H2-receptor antagonist). This suppressive action is dose-dependent. As a result, the production and secretion, particularly of gastric acid, are reduced. Roxatidine acetate has no antiandrogenic effects and does not influence drug-metabolizing enzymes in the liver.

Mechanism of action

The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: histamine released by ECL cells in the stomach is blocked from binding on parietal cell H2 receptors which stimulate acid secretion, and other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked.

TargetActionsOrganism
AHistamine H2 receptor
antagonist
Humans
Absorption

Well absorbed orally (80–90% bioavailability).

Volume of distribution

Not Available

Protein binding

5-7%

Metabolism

Roxatidine acetate is rapidly metabolised to the primary, active desacetyl metabolite.

Route of elimination

Not Available

Half-life

5-6 hours

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Oral, mouse LD50: 1000 mg/kg

Pathways
PathwayCategory
Roxatidine Acetate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmphetamineAmphetamine may decrease the sedative activities of Roxatidine acetate.
AmprenavirRoxatidine acetate can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsunaprevirRoxatidine acetate can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AtazanavirRoxatidine acetate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
BenzphetamineBenzphetamine may decrease the sedative activities of Roxatidine acetate.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Roxatidine acetate hydrochloride60426GOR1E93793-83-0FEWCTJHCXOHWNL-UHFFFAOYSA-N
International/Other Brands
Roxit

Categories

ATC Codes
A02BA06 — Roxatidine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Benzylpiperidines
Direct Parent
N-benzylpiperidines
Alternative Parents
Benzylamines / Phenol ethers / Phenoxy compounds / Phenylmethylamines / Alkyl aryl ethers / Aralkylamines / Amino acids and derivatives / Carboxylic acid esters / Secondary carboxylic acid amides / Trialkylamines
show 6 more
Substituents
Alkyl aryl ether / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Benzylamine / Carbonyl group / Carboxamide group
show 19 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
ZUP3LSD0DO
CAS number
78628-28-1
InChI Key
SMTZFNFIKUPEJC-UHFFFAOYSA-N
InChI
InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)
IUPAC Name
[(3-{3-[(piperidin-1-yl)methyl]phenoxy}propyl)carbamoyl]methyl acetate
SMILES
CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1

References

General References
  1. Murdoch D, McTavish D: Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. Drugs. 1991 Aug;42(2):240-60. [Article]
  2. Product Insert [Link]
Human Metabolome Database
HMDB0015695
KEGG Drug
D08495
PubChem Compound
5105
PubChem Substance
99445276
ChemSpider
4926
BindingDB
50404032
RxNav
114817
ChEBI
94758
ChEMBL
CHEMBL46102
ZINC
ZINC000003812908
PharmGKB
PA165958424
Wikipedia
Roxatidine_acetate
MSDS
Download (1.19 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedNot AvailableCommunity Acquired Pneumonia (CAP) / Gastro-esophageal Reflux Disease (GERD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, coated
Tablet, extended release
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)145-146 for HCl saltMSDS
Predicted Properties
PropertyValueSource
Water Solubility0.0612 mg/mLALOGPS
logP2.27ALOGPS
logP1.31Chemaxon
logS-3.8ALOGPS
pKa (Strongest Acidic)14.88Chemaxon
pKa (Strongest Basic)8.74Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area67.87 Å2Chemaxon
Rotatable Bond Count10Chemaxon
Refractivity96.32 m3·mol-1Chemaxon
Polarizability39.26 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9475
Blood Brain Barrier+0.8366
Caco-2 permeable-0.6032
P-glycoprotein substrateSubstrate0.7781
P-glycoprotein inhibitor IInhibitor0.7868
P-glycoprotein inhibitor IINon-inhibitor0.675
Renal organic cation transporterNon-inhibitor0.645
CYP450 2C9 substrateNon-substrate0.7803
CYP450 2D6 substrateNon-substrate0.8415
CYP450 3A4 substrateSubstrate0.5264
CYP450 1A2 substrateNon-inhibitor0.9143
CYP450 2C9 inhibitorNon-inhibitor0.8237
CYP450 2D6 inhibitorNon-inhibitor0.6876
CYP450 2C19 inhibitorNon-inhibitor0.7797
CYP450 3A4 inhibitorNon-inhibitor0.9203
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6467
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9324
BiodegradationNot ready biodegradable0.5199
Rat acute toxicity2.0100 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8833
hERG inhibition (predictor II)Inhibitor0.5448
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0006-9760000000-71f6584b19a0f5b1ab87
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-3194000000-6595226bd57e8bec27a9
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9674000000-ee8f7686e9ae479def73
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000w-2390000000-dc35b851623a8691f53b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9300000000-f9ef6f74278ec30ae654
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-052b-9520000000-316baa441923054b3ad1
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-9000000000-33465aff904a75a7eee2
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-200.8208635
predicted
DarkChem Lite v0.1.0
[M-H]-182.87662
predicted
DeepCCS 1.0 (2019)
[M+H]+200.8451635
predicted
DarkChem Lite v0.1.0
[M+H]+185.23462
predicted
DeepCCS 1.0 (2019)
[M+Na]+201.3442635
predicted
DarkChem Lite v0.1.0
[M+Na]+191.32777
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Histamine H2 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Agrawal SS, Alvin Jose M: Roxatidine, an H(2) receptor blocker, is an estrogenic compound--experimental evidence. Syst Biol Reprod Med. 2010 Aug;56(4):286-91. doi: 10.3109/19396368.2010.496894. [Article]

Drug created at October 18, 2010 22:57 / Updated at December 02, 2023 06:58